Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases. Its lead clinical program is pz-cel, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 to treat autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was founded in 1974 and is headquartered in Cleveland, Ohio. Show more

Location: 6555 Carnegie Avenue, Cleveland, OH, 44103, United States | Website: https://www.abeonatherapeutics.com | Industry: Biotechnology | Sector: Healthcare

Market Cap

256.3M

52 Wk Range

$3.93 - $7.54

Previous Close

$4.73

Open

$4.73

Volume

952,938

Day Range

$4.68 - $4.92

Enterprise Value

73.32M

Cash

207.1M

Avg Qtr Burn

-18.73M

Insider Ownership

10.35%

Institutional Own.

66.85%

Qtr Updated

09/30/25

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
ZEVASKYN™ (prademagene zamikeracel) Details Recessive dystrophic epidermolysis bullosa	Approved Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ABO-102 (AAV-based Gene Therapy) Details Mucopolysaccharidosis type IIIA	Phase 1/2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ABO-503 (Gene Therapy) Details X-Linked Retinoschisis	IND Submission	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ABO-101 (AAV-based Gene Therapy) Details Rare diseases, Rare genetic disease, Genetic disorder, Mucopolysaccharidoses, Mucopolysaccharidosis type IIIB	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.